PepGen has previously faced an FDA clinical hold on the investigational new drug application of PGN-ENO51 in the Phase II ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

PepGen is 'temporarily pausing' a Phase 2 study of its exon 51 skipping drug for Duchenne muscular dystrophy, it said Tuesday ...

PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.

A Boston biotech's decision to pause a Duchenne muscular dystrophy study has resulted in a significant stock drop.

While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

PepGen (PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne ...

PepGen (NASDAQ:PEPG – Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, ...

AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 ...

Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for PepGen in a report issued on Monday, February 24th. HC Wainwright analyst A. Fein expects that the company will earn ...

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...